Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio
In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the US biosimilar ranibizumab, CIMERLI, from Coherus BioSciences, Inc. The deal, valued at an upfront cash purchase of USD 170 million, encompasses a biologics license application, product inventory, specialized ophthalmology sales […]